Valuing SF-6Dv2 in Australia Using an International Protocol.

Brendan J MulhernRichard NormanJohn Brazier

Published in: PharmacoEconomics (2021)

The model including the Design 1 data and moderating interaction was chosen for the Australian value set. This allows the SF-6Dv2 to be used in health technology assessment decision making in Australia.

Keyphrases

healthcare
public health
randomized controlled trial
electronic health record
mental health
social support
big data
health information
health promotion
machine learning
depressive symptoms
artificial intelligence
risk assessment
data analysis
human health